Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Am J Psychiatry. 2016 Nov 18;174(4):362–369. doi: 10.1176/appi.ajp.2016.16020226

Table 2.

Frequency of relapse by Neuropsychiatric Inventory (NPI) domain symptom severity at baseline and 16 weeks, and risperidone continuation versus discontinuation in the randomized phase (weeks 16 to 32).

NPI Domains Symptom
Severity		 # of relapses by week 32
(n/total)		 p-value2
Risperidone
Continued		 Risperidone
Discontinued
At Baseline
(Week 0)		 Hallucination Absent 13 / 44 11 / 23 0.35
Mild 6 / 19 3 / 6
Severe 4 / 7 10 / 11
Delusions Absent 5 / 11 0 / 4 0.44
Mild 6 / 28 7 / 9
Severe 12 / 31 17 / 27
Agitation/Aggression Absent 2 / 3 4 / 5 0.15
Mild 11 / 33 6 / 15
Severe 10 / 34 14 / 20
Depression/Dysphoria Absent 13 / 41 11 / 21 0.14
Mild 8 / 25 11 / 16
Severe 2 / 4 2 / 3
Anxiety Absent 7 / 25 20 / 29 0.17
Mild 10 / 32 3 / 8
Severe 6 / 13 1 / 3
Elation/Euphoria1 Absent 22 / 64 23 / 38 0.88
Present 1 / 6 1 / 2
Apathy/Indifference Absent 15 / 44 14 / 22 0.07
Mild 1 / 13 8 / 13
Severe 7 / 13 2 / 5
Disinhibition Absent 14 / 38 10 / 19 0.38
Mild 6 / 23 11 / 15
Severe 3 / 9 3 / 6
Irritability/Lability* Absent 6 / 17 4 / 11 0.03
Mild 13 / 32 7 / 15
Severe 4 / 21 13 / 14
Aberrant Motor Absent 12 / 39 15 / 26 0.65
Mild 6 / 15 4 / 6
Severe 5 / 16 5 / 8
Sleep Absent 15 / 49 20 / 32 0.27
Mild 3 / 14 3 / 6
Severe 5 / 7 1 / 2
Appetite Absent 12 / 39 14 / 24 0.33
Mild 8 / 19 4 / 9
Severe 3 / 12 6 / 7
At
Randomization
(Week 16)		 Hallucination Absent 19 / 60 21 / 35 0.31
Mild 4 / 10 3 / 5
Delusions1,* Absent 15 / 50 19 / 24 0.02
Present 8 / 20 5 / 16
Agitation/Aggression Absent 12 / 36 15 / 24 0.82
Mild 11 / 32 8 / 15
Severe 0 / 2 1 / 1
Depression/Dysphoria Absent 17 / 57 19 / 33 0.97
Mild 4 / 11 5 / 7
Severe 2 / 2 0 / 0
Anxiety Absent 12 / 47 19 / 30 0.10
Mild 10 / 22 5 / 10
Severe 1 / 1 0 / 0
Elation/Euphoria Absent 23 / 69 24 / 40 NA
Severe 0 / 1 0 / 0
Apathy/Indifference Absent 11 / 39 18 / 29 0.36
Mild 9 / 20 5 / 9
Severe 3 / 11 1 / 2
Disinhibition1 Absent 18 / 62 19 / 33 0.29
Present 5 / 8 5 / 7
Irritability/Lability Absent 17 / 44 17 / 26 0.89
Mild 6 / 26 7 / 14
Aberrant Motor Absent 14 / 46 20 / 31 0.68
Mild 6 / 18 3 / 6
Severe 3 / 6 1 / 3
Sleep Absent 18 / 59 20 / 33 0.56
Mild 3 / 8 2 / 4
Severe 2 / 3 2 / 3
Appetite Absent 21 / 56 22 / 34 0.40
Mild 1 / 11 2 / 6
Severe 1 / 3 0 / 0
*

p<0.05

1

Due to the small number of patients with severe symptoms, severe and mild symptom groups were merged and are classified as Present.

2

P-values for the interaction between risperidone discontinuation status and symptom severity in the stratified Cox proportional hazard regression models. Stratification factors were nursing home status and presence of psychosis.